Kisho

hyperphosphatemia chronic kidney disease+1 moreTrials & approvals

R1 Therapeutics has commenced a global Phase 2b trial of AP306 for hyperphosphatemia in patients with chronic kidney disease on dialysis. This first-in-class pan phosphate transporter inhibitor aims to address a significant unmet need in this patient population.

REDWOOD CITY, Calif., July 21, ... a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced that the first patient has been randomized in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of ... REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced that the first patient has been randomized in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. It is being conducted at multiple clinical sites across the US and in China through R1's global partnership with Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) ("Alebund"). Hyperphosphatemia is one of the most common complications of advanced CKD and is almost universal in patients on dialysis. It is an independent risk factor for cardiovascular disease, bone disease, and mortality,1 yet more than 70% of US dialysis patients fail to achieve normal phosphate levels.2 Phosphate binders, the standard of care for 60 years, are limited by high pill burden and suboptimal gastrointestinal tolerance, contributing to poor adherence.3 Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled. AP306 is a first-in-class pan phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden.

Treatment & Clinical News2 months agoRead at source →

Original title: “R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis - BioSpace”

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study published in PubMed explores metabolomic responses to oral glucose tolerance tests and hyperinsulinemic-euglycemic clamps in chronic kidney disease (CKD) patients. The findings may provide insights into metabolic dysregulation in CKD, potentially guiding future therapeutic strategies.

A rare case study highlights the relationship between hypertriglyceridemia, chronic kidney disease, and proteinuria in a patient with apolipoprotein C-II amyloidosis. This research contributes to the understanding of the disease's impact on kidney function.

A recent study published in PubMed explores the clinical and genetic characteristics of hypoparathyroidism, deafness, and renal dysplasia syndrome within a chronic kidney disease cohort. This research provides valuable insights into the genetic underpinnings of this rare syndrome.

A narrative review examines the effects of SGLT2 inhibitors on elderly patients with chronic kidney disease. The findings contribute to understanding treatment outcomes in this vulnerable population.

A systematic review highlights the pathomechanisms and risk factors associated with calciphylaxis in chronic kidney disease, focusing on calcific uremic arteriolopathy. This research provides insights that could inform future therapeutic strategies.

A new study explores the link between mineral dysregulation in chronic kidney disease and its impact on bone and cardiovascular health. This research highlights the complex interplay of these conditions, providing insights for future therapeutic strategies.

FDA classifies a prognostic test for assessing chronic kidney disease progression into class II, indicating it will now be subject to special controls. This classification aims to enhance the regulatory framework for devices used in monitoring kidney disease.

R1 Therapeutics has commenced a global Phase 2b trial of AP306 for hyperphosphatemia in patients with chronic kidney disease on dialysis. This first-in-class pan phosphate transporter inhibitor aims to address a significant unmet need in this patient population.

The discussion highlights the critical role of SGLT2 inhibitors and GLP-1 receptor agonists in managing cardiovascular risk in patients with type 2 diabetes and chronic kidney disease. It emphasizes the need for early intervention to reduce morbidity and mortality associated with these conditions.

A study from the THAI-CKD Registry highlights regional variations in the causes and complications of chronic kidney disease in Thailand. This research provides valuable insights into the epidemiology of the disease, which may inform targeted interventions.

A case report highlights the use of kidney imaging in diagnosing and monitoring a patient with primary hyperoxaluria type 1 and severe chronic kidney disease. The study reviews existing literature, contributing to the understanding of this rare condition.

A case report highlights the occurrence of uremic pancreatitis after starting losartan in a patient with advanced chronic kidney disease. This finding may prompt further investigation into the safety of losartan in this patient population.

A recent study investigates the impact of comorbid chronic kidney disease on late-onset hypophosphatasia in mice treated with asfotase alfa. The findings contribute to understanding the complexities of managing this rare disease in patients with additional health conditions.

A rare case study highlights a bloodstream infection caused by Comamonas testosteroni in a patient with stage 5 chronic kidney disease undergoing maintenance hemodialysis. This case underscores the potential for unusual infections in immunocompromised patients.

R1 has secured $78 million in funding to develop a new oral treatment for a common complication of chronic kidney disease, licensed from a Chinese biotech. The startup aims to offer a more potent and convenient alternative to current therapies.

The Italian Society of Nephrology has released expert consensus recommendations on utilizing telemedicine to improve care for chronic kidney disease. This initiative aims to enhance patient management and accessibility in nephrology.

A study investigates the effects of dapagliflozin in patients with chronic kidney disease (CKD) associated with Fabry disease. The findings contribute to understanding potential treatment options for this rare condition.

Not rare diseases news,news about your rare disease.

Earlier

A rare case study highlights the relationship between hypertriglyceridemia, chronic kidney disease, and proteinuria in a patient with apolipoprotein C-II amyloidosis. This research contributes to the understanding of the disease's impact on kidney function.

A recent study published in PubMed explores the clinical and genetic characteristics of hypoparathyroidism, deafness, and renal dysplasia syndrome within a chronic kidney disease cohort. This research provides valuable insights into the genetic underpinnings of this rare syndrome.

A narrative review examines the effects of SGLT2 inhibitors on elderly patients with chronic kidney disease. The findings contribute to understanding treatment outcomes in this vulnerable population.

A systematic review highlights the pathomechanisms and risk factors associated with calciphylaxis in chronic kidney disease, focusing on calcific uremic arteriolopathy. This research provides insights that could inform future therapeutic strategies.

A new study explores the link between mineral dysregulation in chronic kidney disease and its impact on bone and cardiovascular health. This research highlights the complex interplay of these conditions, providing insights for future therapeutic strategies.

FDA classifies a prognostic test for assessing chronic kidney disease progression into class II, indicating it will now be subject to special controls. This classification aims to enhance the regulatory framework for devices used in monitoring kidney disease.

R1 Therapeutics has commenced a global Phase 2b trial of AP306 for hyperphosphatemia in patients with chronic kidney disease on dialysis. This first-in-class pan phosphate transporter inhibitor aims to address a significant unmet need in this patient population.

The discussion highlights the critical role of SGLT2 inhibitors and GLP-1 receptor agonists in managing cardiovascular risk in patients with type 2 diabetes and chronic kidney disease. It emphasizes the need for early intervention to reduce morbidity and mortality associated with these conditions.

A study from the THAI-CKD Registry highlights regional variations in the causes and complications of chronic kidney disease in Thailand. This research provides valuable insights into the epidemiology of the disease, which may inform targeted interventions.

A case report highlights the use of kidney imaging in diagnosing and monitoring a patient with primary hyperoxaluria type 1 and severe chronic kidney disease. The study reviews existing literature, contributing to the understanding of this rare condition.

A case report highlights the occurrence of uremic pancreatitis after starting losartan in a patient with advanced chronic kidney disease. This finding may prompt further investigation into the safety of losartan in this patient population.

A recent study investigates the impact of comorbid chronic kidney disease on late-onset hypophosphatasia in mice treated with asfotase alfa. The findings contribute to understanding the complexities of managing this rare disease in patients with additional health conditions.

A rare case study highlights a bloodstream infection caused by Comamonas testosteroni in a patient with stage 5 chronic kidney disease undergoing maintenance hemodialysis. This case underscores the potential for unusual infections in immunocompromised patients.

R1 has secured $78 million in funding to develop a new oral treatment for a common complication of chronic kidney disease, licensed from a Chinese biotech. The startup aims to offer a more potent and convenient alternative to current therapies.

The Italian Society of Nephrology has released expert consensus recommendations on utilizing telemedicine to improve care for chronic kidney disease. This initiative aims to enhance patient management and accessibility in nephrology.

A study investigates the effects of dapagliflozin in patients with chronic kidney disease (CKD) associated with Fabry disease. The findings contribute to understanding potential treatment options for this rare condition.

Not rare diseases news,
news about your rare disease.